Advertisement

Erkrankungen des Blutes

  • Daniel Re
  • Jürgen Wolf
  • Dimitris Voliotis
  • Rüdiger Hehlmann
  • Eva Lengfelder
  • Ute Berger
  • Andreas Reiter
  • Andreas Hochhaus
  • Carlo Aul
  • Aristoteles Giagounidis
  • Ulrich Germing
  • Aruna Raghavachar
  • Norbert Frickhofen
  • Peter Staib
  • Pia Hartmann
  • Markus Sieber
  • Volker Diehl
  • Marcel Reiser
  • Andreas Engert
  • Dimitris Voliotis
  • Dietmar Söhngen

Zusammenfassung

Die hämatopoetischen Stammzellen sind charakterisiert durch die Fähigkeit zur Selbsterneuerung und Differenzierung in Progenitorzellen (Vorläuferzellen). Von diesen Vorläuferzellen stammen alle zellulären Bestandteile des Blutes ab. Die beim Erwachsenen im Knochenmark vorkommende pluripotente hämatopoetische Stammzelle steht somit am Beginn der Entwicklung aller hämatopoetischen Reihen (lymphozytär, myeloisch, erythrozytär und megakaryozytär). Die Proliferation und die Differenzierung dieser Zellen werden unter anderem durch das komplexe Zusammenspiel von Wachstumsfaktoren (Zytokinen) sowie von Zell-Zell-und Zell-Matrix-Interaktionen reguliert. Im Folgenden werden die zugrunde liegenden pathophysiologischen Konzepte dargestellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Domen J, Weissman IL (1999) Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate. Mol Med Today 5: 201–208PubMedGoogle Scholar
  2. Enver T, Heyworth CM, Dexter TM (1998) Do stem cells play dice? Blood 92: 348–351PubMedGoogle Scholar
  3. Gussoni E, Soneoka Y, Strickland CD et al. (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401: 390–394PubMedGoogle Scholar
  4. Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C, Enver T (1997) Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 11: 774–785PubMedGoogle Scholar
  5. Petersen BE, Bowen WC, Patrene KD et al. (1999) Bone marrow as a potential source of hepatic oval cells. Science 284: 1168–1170PubMedGoogle Scholar
  6. Zon LI (1995) Developmental biology of hematopoiesis. Blood 86: 2876–2891PubMedGoogle Scholar
  7. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states. Experience in 577 patients. Am J Med 92: 69–76Google Scholar
  8. Chronic Myeloid Leukemia Trialists’ Collaborative Group (1997) Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89: 1616–1620Google Scholar
  9. Cortelazzo S, Finazzi G, Ruggeri M et al. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332: 1132–1136PubMedGoogle Scholar
  10. Gratwohi A, Hermans J, Goldman IM et al. (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 352: 1087–1092Google Scholar
  11. Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst 90: 850–858PubMedGoogle Scholar
  12. Kantarjian H, Sawyers CL, Hochhaus A et al. (2002) Glivec/GleevecTM (imatinib mesylate) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study. N Engl J Med 346: 645–652PubMedGoogle Scholar
  13. Lengfelder E, Hochhaus A, Kronawitter U et al. (1998) Should a platelet limit of 600 x10 9/1 be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages. Brit J Haematol 100: 15–23Google Scholar
  14. Löfvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41: 375–381Google Scholar
  15. Sawyers CL, Hochhaus A, Feldman E et al. (2002) Gleevec/GlivecTM (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530–3539PubMedGoogle Scholar
  16. Silver RT, Woolf SH, Hehlmann R et al. (1999) Review: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94: 1517–1536Google Scholar
  17. Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342, 1255–1265PubMedGoogle Scholar
  18. Packmann C (1998) Pathogenesis and management of paroxys- mal nocturnal hemoglobinuria. Blood Reviews 12: 1–11Google Scholar
  19. Saso R, Marsh J, Cevreska L et al. (1999) Bone marrow transplants for paroxysmal nocturnal hemoglobinuria. Br J Haematol 104: 392–396Google Scholar
  20. Suenaga K, Kanda Y, Niiya H et al. (2001) Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol 29: 639–642PubMedGoogle Scholar
  21. Delannay J, Iolascon A (1999) The congenital dyserythropoietic anemias. Best Pract Res Clin Haematol 12: 691–705Google Scholar
  22. Iolascon A, Sabato V, de Mattia D, Loctalli F (2001) Bone marrow transplantation in a case of severe, type II congenital dyserythropoetic anemia ( CD II ). Bone Marrow Transplant 27: 213–215Google Scholar
  23. Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341 (26): 1986–1995PubMedGoogle Scholar
  24. Barkin JS, Ross BS (1998) Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol 93 (8): 1250–1254PubMedGoogle Scholar
  25. Goddard AF, McIntyre AS, Scott BB (2000) Guidelines for the management of iron deficiency anemia. British Society of Gastroenterology. Gut 46(Suppl 3–4): IV 1-IV5Google Scholar
  26. Rockey DC (1999) Occult gastrointestinal bleeding. N Engl J Med 341 (1): 38–46PubMedGoogle Scholar
  27. Zuckerman GR, Prakash C, Askin MP, Lewis BS (2000) AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 118(1): 201–221 (AGA position statement: 197–201 )Google Scholar
  28. Carmel R (1996) Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 156 (10): 1097–1100PubMedGoogle Scholar
  29. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA (2000) Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343 (22): 1608–1614PubMedGoogle Scholar
  30. Hofíbrand AV, Herbert V (1999) Nutritional anemias. Semin Hematol 36 (4, Supp17): 13–23Google Scholar
  31. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340 (19): 1449–1454PubMedGoogle Scholar
  32. Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H (1998) The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anemia. A prospective follow-up study. Scand J Gastroenterol 33 (1): 88–92PubMedGoogle Scholar
  33. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J (1998) Effective treatment of cobalamin deficiency with oral cobalamin. Blood 92 (4): 1191–1198PubMedGoogle Scholar
  34. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH (1994) Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 60 (1): 2–11PubMedGoogle Scholar
  35. Stabler SP, Allen RH, Savage DG, Lindenbaum J (1990) Clinical spectrum and diagnosis of cobalamin deficiency. Blood 76 (5): 871–881PubMedGoogle Scholar
  36. Toh BH, van Driel IR, Gleeson PA (1997) Pernicious anemia. N Engl J Med 337 (20): 1441–1448PubMedGoogle Scholar
  37. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J (1996) Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 276 (23): 1879–1885PubMedGoogle Scholar
  38. Brittenham GM, Griffith PM, Nienhuis AW et al. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331: 567PubMedGoogle Scholar
  39. Castro 0 (1999) Management of sickle cell disease: Recent advances and controversies. Br J Haemotol 107: 2Google Scholar
  40. Charache S, Terrin ML, Moore RD et al. (1995) The investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332: 1317Google Scholar
  41. Chemnitz J, Schulz A, Diehl V, Söhngen D (2001) Thrombotischthromobozytopenische Purpura (Moschcowitz-Syndrom). Med Klin 96 (6): 343Google Scholar
  42. Ehlers KH, Giardina PJ, Lesser ML et al. (1991) Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 118: 540PubMedGoogle Scholar
  43. Kawahara K, Witherspoon RP, Storb R (1992) Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol 39: 283PubMedGoogle Scholar
  44. Kwan T, Hansard P (1992) Recombinant tissue-plasminogen activator for acute Budd-Chiari syndrome secondary to paroxysmal nocturnal hemoglobinuria. NY State J Med 92: 88Google Scholar
  45. Lee EJ, Kueck B (1998) Rituxan in the treatment of cold agglutinin disease. Blood 92 (9): 3490PubMedGoogle Scholar
  46. Petz LD (2001) Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 8 (6): 411PubMedGoogle Scholar
  47. Propper RD, Cooper B, Rufo RR et al. (1977) Continous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 297: 418PubMedGoogle Scholar
  48. Rock GA, Shumak KH, Buskard NA et al. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325: 393Google Scholar
  49. Rosse WF, Guttermann LA (1970) The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood 36: 559PubMedGoogle Scholar
  50. Sanchez-Valle E, Morales-Polanca MR, Gomez-Morales E et al. (1993) Treatment of paroxysmal nocturnal hemoglobinuria with antilymphocyte globulin. Rev Invest Clin 45: 457PubMedGoogle Scholar
  51. Walters MC et al. (1996) Bone marrow transplantation for sickle cell disease. N Engl J Med 335: 369PubMedGoogle Scholar
  52. Zecca M, De Stefano P, Nobili B, Locatelli F (2001) Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97 (12): 3995PubMedGoogle Scholar
  53. Bron D, Meuleman N, Mascaux C (2001) Biological basis of anemia. Semin Oncol 28 (2 Supp18): 1–6PubMedGoogle Scholar
  54. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (11): 2865–2874PubMedGoogle Scholar
  55. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ (1996) Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 55 (10): 739–744PubMedGoogle Scholar
  56. Spivak JL (2000) The blood in systemic disorders. Lancet 355 (9216): 1707–1712PubMedGoogle Scholar
  57. Weinstein DA (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100: 3776–3781PubMedGoogle Scholar
  58. Wians FH Jr, Urban JE, Keffer JH, Kroft SH (2001) Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol 115 (1): 112–118PubMedGoogle Scholar
  59. Bishop JF, Matthews JP, Young GA et al. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87(5): 1710–1717Google Scholar
  60. Büchner T, Hiddemann W, Wörmann B et al. (1997) Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 24 (1): 124–131PubMedGoogle Scholar
  61. Büchner T, Hiddemann W, Wörmann B et al. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. a randomized trial by the German AML Cooperative Group. Blood 93: 4116–4124PubMedGoogle Scholar
  62. Büchner T, Hiddemann W, Berdel W et al. (2002) Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 6 (1): 46–59PubMedGoogle Scholar
  63. Cassileth PA, Harrington DP, Appelbaum FR et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (23): 1649–1656PubMedGoogle Scholar
  64. Harousseau JL, Calm JY, Pignon B et al. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 90 (8): 2978–2986PubMedGoogle Scholar
  65. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
  66. Lengfelder E, Reichert A, Schoch C et al. (2000) Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14 (8): 1362–1370PubMedGoogle Scholar
  67. Mayer RJ, Davis RB, Schiffer CA et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (14): 896–903PubMedGoogle Scholar
  68. Zittoun RA, Mandelli F, Willemze R et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dellAdulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (4): 217–223PubMedGoogle Scholar
  69. Bain BJ (2000) Hypereosinophilia. Curr Opin Hematol 7 (1): 21–25PubMedGoogle Scholar
  70. Kim HS, Chun YS, Chang SN, Park WH (2001) Hypereosinophilic syndrome: correlation between clinical severity and cutaneous microthrombi. Int J Dermatol 40 (5): 330–332PubMedGoogle Scholar
  71. Oliver JW, Deol I, Morgan DL, Tonk VS (1998) Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 107 (2): 111–117PubMedGoogle Scholar
  72. Borges WG, Augustine NH, Hill HR (2000) Defective interleukin12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 136 (2): 176–180Google Scholar
  73. Erlewyn-Lajeunesse MD (2000) Hyperimmunoglobulin-E syndrome with recurrent infection: a review of current opinion and treatment. Pediatr Allergy Immunol 11 (3): 133–141PubMedGoogle Scholar
  74. Introne W, Boissy RE, Gahl WA (1999) Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 68 (2): 283–303PubMedGoogle Scholar
  75. Shemer A, Weiss G, Confino Y, Trau H (2001) The hyper-IgE syndrome. Two cases and review of the literature. Int J Dermatol 40 (10): 622–628PubMedGoogle Scholar
  76. Ward DM, Griffiths GM, Stinchcombe JC, Kaplan J (2000) Analysis of the lysosomal storage disease Chediak-Higashi syndrome. Traffic 1 (11): 816–822PubMedGoogle Scholar
  77. Beauchesne MF, Shalansky SJ (1999) Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 19 (3): 299–305PubMedGoogle Scholar
  78. Hughes WT, Armstrong D, Bodey GP et al. (Infectious Diseases Society of America) (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25(3): 551–573Google Scholar
  79. Bohm P, Kunz W, Horny HP, Einsele H (2001) Adult Gaucher disease in association with primary malignant bone tumors. Cancer 91 (3): 457–462PubMedGoogle Scholar
  80. Mankin HJ, Rosenthal DI, Xavier R (2001) Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg Am 83-A(5): 748–762Google Scholar
  81. Niederau C, Rolfs A, vom Dahl S, Haussinger D, Poll LW, Mengel E, Beck M (2001) Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000. Med Klin 96 (1): 32–39Google Scholar
  82. Hartmann K, Bruns SB, Henz BM (2001) Mastocytosis: review of clinical and experimental aspects. J Investig Dermatol Symp Proc 6 (2): 143–147PubMedGoogle Scholar
  83. Horny HP, Valent P (2001) Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 25 (7): 543–551PubMedGoogle Scholar
  84. Ludolph-Hauser D, Rueff F, Sommerhoff CP, Przybilla B (1999) Tryptase, a marker for the activation and localization of mast cells. Hautarzt 50 (8): 556–561PubMedGoogle Scholar
  85. Marone G, Spadaro G, Granata F, Triggiani M (2001) Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 25 (7): 583–594PubMedGoogle Scholar
  86. Metcalfe DD, Akin C (2001) Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 25 (7): 577–582PubMedGoogle Scholar
  87. Valent P, Horny HP, Escribano L et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 (7): 603–625PubMedGoogle Scholar
  88. Gadner H (1999) Langerhans’ cell histiocytosis–still an unsolved problem. Ped Hematol Oncol 16: 1–5Google Scholar
  89. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H (2000) Treatment of multisystem Langerhans cell histiocytosis. Results of DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 214 (4): 139–144Google Scholar
  90. Gadner H, Grois N, Arico M and the Histiocyte Society (2001) A randomised trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 138 (5): 728–734Google Scholar
  91. Histiocyte Society (2001) LCH-III, treatment protocol of the third international study for Langerhans cell histiocytosis.Google Scholar
  92. Canellos et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327: 1478PubMedGoogle Scholar
  93. Carde P, Noordijk EM, Hagenbeek A et al. (1997) Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin On-col 16: Abstr 44Google Scholar
  94. Diehl V, Franklin J, Sieber M et al. (2000) Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin’s disease: Updated results of the German Hodgkin’s Lymphoma Sudy Group. Blood 2000; 96 (Suppl. 1 ) 2474AGoogle Scholar
  95. Diehl V (1998) Deutsche Hodgkin Lymphom Studiengruppe. HD1O-HD12 Studienprotokolle der Primärtherapie, KölnGoogle Scholar
  96. Jaffe ES, Harris NL, Diebold J, Muller Hermelink HK (1999) World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111: 8Google Scholar
  97. Josting A, Diehl V, Engert A (2000) Behandlung and Prognose primär progredienter and rezidivierter Hodgkin-Lymphome. Onkologe 6 (12): 1178–1188Google Scholar
  98. Küppers R, Re D, Wolf J, Diehl V (2000) Zellbiologie des Morbus Hodgkin. Onkologe 6 (12): 1134–1141Google Scholar
  99. Rüffer JU, Breuer K, Flechtner H (2000) Lebensqualität and Lebensquantität bei Morbus Hodgkin. Onkologe 6 (12): 1189–1196Google Scholar
  100. Sieber M, Engert A, Diehl V (2000) Treatment of Hodgkin’s disease: Results and current concepts of the German Hodgkin’s Lymphoma Study Group. Ann Oncol 11 (Suppl 1): 81–85PubMedGoogle Scholar
  101. Allen I, Ross S, Borden S, Monroe M, Kupelnick B, Connelly J et al. (2001) Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin’s lymphoma. J Immunother 24 (1): p58–65Google Scholar
  102. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18 (3): 527–536PubMedGoogle Scholar
  103. Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16 (8): 2780–95PubMedGoogle Scholar
  104. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (4): 235–242PubMedGoogle Scholar
  105. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328 (14): 1002–1006PubMedGoogle Scholar
  106. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 10 (12): 1419–1432PubMedGoogle Scholar
  107. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (5): 1361–1392PubMedGoogle Scholar
  108. Isaacson PG (1999) Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36 (2): 139–147PubMedGoogle Scholar
  109. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333 (23): 1540–1545PubMedGoogle Scholar
  110. Giona F, Annino L, Rondelli R et al. (1997) Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: Results of the ALL R-87 protocol. Br J Haematol 97: 896PubMedGoogle Scholar
  111. Hoelzer D, Ludwig W-D, Thiel E, Gabmann W, Löffler H, Fonatsch C et al. (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87: 495PubMedGoogle Scholar
  112. Koller CA, Kantarjian HM, Thomas D et al. (1997) The HCVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 11: 2039PubMedGoogle Scholar
  113. Laport GF, Larson RA (1997) Treatment of acute lymphoblastic leukemia in adults. Semin Oncol 24: 70PubMedGoogle Scholar
  114. Larson RA, Dodge RK, Bloomfield CD, Schiffer CA (1997) Treatment of biologically determined subsets of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B studies. In: Buchner T, Hiddeman W, Wormann B, Ritter J, Schellong G (eds) Acute leukemias VI: Prognostic factors and treatment strategies. Springer, Berlin Heidelberg New York Tokyo, p 677Google Scholar
  115. Ludwig W-D, Rieder H, Bartram CR, Heinze B, Schwartz S, Gass-mann Wet al. (1998) Immunophenotype and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood 92: 1898–1909PubMedGoogle Scholar
  116. Reiter A, Schrappe M, Ludwig W, Lampert F, Harbott J, Henze G et al. (1992) Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group. Blood 80: 2471Google Scholar
  117. Roberts WM, Estrov Z, Ouspenskaia MV et al. (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336: 317PubMedGoogle Scholar
  118. Sierra J, Radich J, Hansen JA et al. (1997) Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90: 1410PubMedGoogle Scholar
  119. Zhang MJ, Hoelzer D, Horowitz MM et al. (1995) Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 123: 428PubMedGoogle Scholar
  120. Anderson KC (2001) Targeted therapy for multiple myeloma. Se-min Hematol 38: 286–294Google Scholar
  121. Attal M, Harousseau JL, Stoppa AM et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91–97PubMedGoogle Scholar
  122. Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353–1356PubMedGoogle Scholar
  123. Bataille R, Harousseau JL (1997) Multiple myeloma ( Review Article ). N Engl J Med 36: 1657–1664Google Scholar
  124. Bensinger WI, Buckner D, Anasetti C et al. (1998) Allogeneic bone marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88: 2787–2793Google Scholar
  125. Davies FE, Anderson KC (2000) Novel therapeutic targets in multiple myeloma. Eur J Hematol 64: 359–367Google Scholar
  126. Desikan R, Barlogie B, Sawyer J et al. (2000) Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 95: 4008–4010PubMedGoogle Scholar
  127. Myeloma Trialists Collaborative Group, Pasquali S, Maqueo JD, Vela J et al. (1998) Combination chemotherapy versus Melphalan plus Prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16(12): 3832–3842Google Scholar
  128. Singhal S, Mehta J, Desikan R et al. (1999) Anti tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1566–1571Google Scholar
  129. Tricot G, Vesole DH, Jagannath S et al. (1996) Graft-versus myeloma effect: proof of principle. Blood 87: 1196–1198PubMedGoogle Scholar
  130. Burstein SA (2000) Thrombocytopenia due to decreased platelet production. In: Hoffman, R, Benz EJ, Shattil SJ et al. (Hrsg) Hematology. Basic Principles and Practice, 3`d edn. Churchill Livingstone, New York, pp 2115–2125Google Scholar
  131. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, Söhngen D (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71: 105–108PubMedGoogle Scholar
  132. Cines DB, Blanchette VS (2002) Medical progress. Immune thrombocytopenic purpura. N Engl J Med 346: 995–1008Google Scholar
  133. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R (1955) Hämolytisch-urämisches Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 85: 905–909Google Scholar
  134. George JN (2001) Platelet kinetics and pathophysiology of thrombocytopenia. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (Hrsg) Hemostasis and thrombosis. Basic principles and clinical practice, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 447–459Google Scholar
  135. George JN (2002) Platelets. Lancet 355: 1531–1539Google Scholar
  136. George JN, Shattil SJ (2000) Acquired disorders of platelet function. In: Hoffman R, Benz EJ, Shattil SJ et al. (Hrsg) Hematology. Basic principles and practice, 3rd edn. Churchill Livingstone, New York, pp 2172–2186Google Scholar
  137. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura ( TTP ). Thromb Haemost 82: 1386–1389Google Scholar
  138. Giagounidis AAN, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, Aul C (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD 20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 69: 95–100PubMedGoogle Scholar
  139. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV (1951) Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 38: 1–10PubMedGoogle Scholar
  140. Kiefel V, Santoso S (1999) Idiopathische thrombozytopenische Purpura und weitere immunologisch bedingte Thrombozytopenien. In: Müller-Berghaus G, Pötzsch B (Hrsg) Hämostaseologie. Molekulare und zelluläre Mechanismen, Pathophysiologie und Klinik. Springer, Berlin Heidelberg New York Tokyo, S 95–106Google Scholar
  141. Moake JL (2002) Mechanisms of disease. Thrombotic microangiopathies. N Engl J Med 347: 589–600PubMedGoogle Scholar
  142. Moschcowitz E (1924) Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 24: 21–24Google Scholar
  143. Barthels M, Poliwoda H (1998) Gerinnungsanalysen. Schnellorientierung, Befundinterpretation, klinische Konsequenzen, 6. Aufl. Thieme, Stuttgart New YorkGoogle Scholar
  144. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (2001) Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 4th edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  145. Greinacher A (1996) Heparin-induzierte Thrombozytopenie. Internist 37: 1172–1178PubMedGoogle Scholar
  146. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (2000) Hematology. Basic Principles and Practice, 3rd edn. Churchill Livingstone, New YorkGoogle Scholar
  147. Leitlinien der Deutschen Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin (2002) Diagnostik und Therapie der Venenthrombose und Lungenembolie. VASA 31 [Suppl 601]Google Scholar
  148. Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer (2001) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Arzte-Verlag, KölnGoogle Scholar
  149. Levine JS, Branch W, Rauch J (2002) Medical progress. The antiphospholipid syndrome. N Engl J Med 346: 752–763Google Scholar
  150. Müller-Berghaus G, Pötzsch B (1999) Hämostaseologie. Molekulare und zelluläre Mechanismen, Pathophysiologie und Klinik. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  151. Seligsohn U, Lubetsky A (2001) Genetic susceptibility to venous thrombosis. N Engl J Med 344: 1222–1231PubMedGoogle Scholar
  152. Söhngen D, Specker C, Bach D (1997) Acquired factor VIII inhi- bitors in nonhemophilic patients. Ann Hematol 74: 89–93PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Daniel Re
  • Jürgen Wolf
  • Dimitris Voliotis
  • Rüdiger Hehlmann
  • Eva Lengfelder
  • Ute Berger
  • Andreas Reiter
  • Andreas Hochhaus
  • Carlo Aul
  • Aristoteles Giagounidis
  • Ulrich Germing
  • Aruna Raghavachar
  • Norbert Frickhofen
  • Peter Staib
  • Pia Hartmann
  • Markus Sieber
  • Volker Diehl
  • Marcel Reiser
  • Andreas Engert
  • Dimitris Voliotis
  • Dietmar Söhngen

There are no affiliations available

Personalised recommendations